膜性肾病患者合并新型冠状病毒感染临床特征及短期预后分析

    Clinical features and short-term outcomes of patients with membranous nephropathy complicated with COVID-19

      摘要
    • 摘要:
      目的  评估新型冠状病毒感染对膜性肾病（membranous nephropathy, MN）患者的影响。
      方法  回顾性分析安徽医科大学附属阜阳人民医院2022年12月15日至2023年1月6日感染新型冠状病毒的61例MN患者的人口学、临床表现、治疗转归及预后等资料。
      结果  （1）61例患者中男性40例（65.6%），年龄（51.7 ± 12.8）岁，31例（50.8%）MN达到临床缓解，51例（83.6%）接种过2剂或以上新冠疫苗。（2）感染新型冠状病毒后MN患者可出现多系统临床症状，前3位分别是发热（78.7%）、咳嗽咳痰（52.5%）、乏力（44.3%）。仅出现1种症状的患者12例（19.7%），3种及以上症状患者41例（67.2%）。依据新型冠状病毒感染诊疗方案（试行第十版）,轻型58例（95.1%），中型3例（4.9%）。（3）MN患者合并新型冠状病毒感染以对症治疗为主，在新型冠状病毒感染后1个月内，多数患者病情稳定，仅1例复发，1例患者并发急性肾损伤。
      结论  MN合并新型冠状病毒感染患者的临床症状较轻，短期预后较好。

       

      Abstract:
      Objective To evaluate the effect of COVID-19 in patients with membranous nephropathy (MN).
      Methods From December 15, 2022 to January 6, 2023, retrospective review was performed for personal demographics, clinical symptoms and treatment outcomes of 61 MN patients with COVID-19.
      Results  There were 40 males and 21 females with a mean age of (51.7±12.8) year. And 31 cases (50.8%) achieved clinical remission and 51 (83.60%) had received two or more doses of COVID-19 vaccine. After an infection of COVID-19, MN patients presented multi-system clinical symptoms. Top three were fever (78.7%), cough & sputum (52.5%) and fatigue (44.3%). Twelve patients (19.7%) had only one symptom and 41 cases (67.2%) had three or more symptoms. According to the Diagnostic and Therapeutic Protocol for Novel Coronavirus Infection (Trial Edition X), 58 cases (95.1%) were mild and 3 (4.9%) medium. MN patients with COVID-19 were treated mostly symptomatically. Within 1 month after COVID-19, most patients stabilized. Only 1 case relapsed and another developed acute kidney injury.
      Conclusions MN patients with COVID-19 have milder clinical symptoms and better short-term outcomes.

       

      • HTML全文
      • 参考文献(29)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回